Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer.

Slamon DJ, Fasching P, Hurvitz S (2023)

Publication Type: Journal article, Erratum

Publication year: 2023

Journal

Therapeutic Advances in Medical Oncology SAGE Publications

Book Volume: 15

DOI: 10.1177/17588359231201818

Abstract

[This corrects the article DOI: 10.1177/17588359231178125.].

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

University of California Los Angeles (UCLA) US United States (USA) (US)

How to cite

APA:

Slamon, D.J., Fasching, P., & Hurvitz, S. (2023). Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Therapeutic Advances in Medical Oncology, 15. https://doi.org/10.1177/17588359231201818

MLA:

Slamon, Dennis J., Peter Fasching, and Sara Hurvitz. "Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer." Therapeutic Advances in Medical Oncology 15 (2023).

BibTeX: Download